360° SearchNetwork Hot Spots Trends Time Series

Publication: Drug Discovery and Development

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Halozyme Reports Pancreatic Cancer Study Data

Halozyme Therapeutics Inc. has released clinical trial data for an experimental cancer drug.Halozyme posted results from an early-stage trial that included its drug PEGPH20 as a treatment for pancreatic cancer. The regimen included PEGPH20 and the cancer ... [Published Drug Discovery and Development - May 17 2013]

Entities: Pancreatic Cancer, Drugs, Tumor, antineoplastic

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Alzheimer's Predicted Before Symptoms Develop

Scientists at Washington University School of Medicine in St. Louis have helped identify many of the biomarkers for Alzheimer’s disease that could potentially predict which patients will develop the disorder later in life. Now, studying spinal fluid samples ... [Published Drug Discovery and Development - May 14 2013]

Entities: Alzheimer's Disease, Joanne Knight, Washington University School of Medicine, cerebrospinal fluid

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Ranbaxy Laboratories Ltd

Impure Drugs Cost Ranbaxy $500M

A subsidiary of India's largest pharmaceutical company has agreed to pay $500 million in fines and civil penalties for selling adulterated drugs and lying about tests of the medications to federal regulators, the U.S. Justice Department said Monday.Prosecutors ... [Published Drug Discovery and Development - May 14 2013]

Entities: Ranbaxy Laboratories Ltd, Drugs, Generic Drug, US Department of Justice, Cosmetics

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Merck KGaA

Rebif Prices Push Merck Up 54%

Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.Merck also saw stronger sales of materials for liquid-crystal displays and raised ... [Published Drug Discovery and Development - May 14 2013]

Entities: Rebif, Merck KGaA, Push

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Pfizer Inc

Pfizer Having Second Thoughts on Remoxy

Pfizer Inc. may not pursue further development of Remoxy, an experimental pain drug that has been plagued with delays in regulatory approval.Durect Corp. developed Remoxy and licensed it to Pain Therapeutics Inc. Pfizer now holds a sublicense from Pain ... [Published Drug Discovery and Development - May 10 2013]

Entities: Remoxy, Pfizer Inc, Pain Therapeutics Inc, Drugs

First reported May 10 2013 - Updated May 10 2013 - 1 reports

ASMS Conference on Mass Spectrometry and Allied Topics

The 61st begins on Sunday, June 9 with tutorial lectures at 5:00 pm and the opening session and plenary lecture at 6:45 pm. A welcome reception in the poster/exhibit hall will follow. Monday through Thursday will be full program days of concurrent oral ... [Published Drug Discovery and Development - May 10 2013]

Entities: Mass Spectrometer, Minneapolis (Minnesota, United States), AVENUE SOUTH LTD

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Almac Out-Licenses ALM201

Almac Discovery announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd. for clinical development and marketing in South Korea. Shin Poong will make an undisclosed upfront payment and pay milestones ... [Published Drug Discovery and Development - May 10 2013]

Entities: Almac Group Ltd, South Korea, Peptide

First reported May 10 2013 - Updated May 10 2013 - 1 reports

AIDS Research May Tackle Drug-Resistant Bacteria

Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells.The National Institutes of ... [Published Drug Discovery and Development - May 10 2013]

Entities: Cystic Fibrosis, AIDS Research, infections, Bacteria, Antibiotic-Resistant

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Alexza Licenses Adasuve to Teva

Alexza Pharmaceuticals Inc. said Teva Pharmaceutical Industries Ltd., one of the world's largest drug companies, will market its agitation drug Adasuve in the United States.The companies said that Teva will be responsible for all U.S. commercial and clinical-related ... [Published Drug Discovery and Development - May 09 2013]

Entities: Teva Pharmaceutical Industries Ltd, Drugs, Scott Henry

First reported May 09 2013 - Updated May 09 2013 - 1 reports

A Target Rich Environment

The 2013 American Association for Cancer Research (AACR) meeting was a showcase for many potential new druggable tumor targets. The range of potential new drug targets introduced was expansive, especially if one counts the whole-exome sequencing work ... [Published Drug Discovery and Development - May 09 2013]

Entities: Cancer, Tumor, Breast Cancer, Patient, Statins

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Producing Orally Bioavailable Biologics

Nick Terrett, Chief Scientic Officer; Ensemble Therapeutics Corp, Cambridge, Mass.click to enlargeDrug developers have been in a quandary for some years now. The Human Genome Project offered novel insights into disease, including numerous tantalizing ... [Published Drug Discovery and Development - May 07 2013]

Entities: bioavailable, Biology, Ensemble Therapeutics Inc

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Actavis Posts 1Q Loss

Generic drugmaker Actavis Inc. said it took a loss in the first quarter on costs related to acquisitions.Actavis combined with Watson Pharmaceuticals in October, and in January the company acquired Belgian drug developer Uteron Pharma to expand its women's ... [Published Drug Discovery and Development - May 03 2013]

Entities: Actavis, Watson Pharmaceuticals Inc, Uteron Pharma

Quotes

"Given the years of delay, additional cost incurred to bring the program to this point and development work left in the program, there will be much to consider when we seek management endorsement" Pfizer wrote

Pfizer Having Second Thoughts on Remoxy [Published Drug Discovery and Development - May 10 2013]

"A key challenge for Merck will be to mitigate the ongoing earnings gap produced by the U S patent expiration of Singulair and several other products with growth in newer products" Moody's noted

Firm May Lower Merck Rating [Published Drug Discovery and Development - May 02 2013]

...So he began sitting in on the Südhof lab's weekly meetings. "We'd just developed this new system, and we were scouting out interesting proteins implicated in nerve-cell signal transmission or, perhaps, in disease states" Brunger said

Likely Role Of "Parkinson's" Protein Found [Published Drug Discovery and Development - May 01 2013]

"This share repurchase program, combined with our strong dividend, reinforces our continued commitment to delivering increased value to shareholders" CEO Kenneth Frazier said in a statement

Competition Cuts Merck Profit [Published Drug Discovery and Development - May 01 2013]

More Content

sort by: Date \| Relevance
Halozyme Reports Pancreatic Cancer Study Data [Published Drug Discovery and Development - May 17 2013]
Impure Drugs Cost Ranbaxy $500M [Published Drug Discovery and Development - May 14 2013]
Rebif Prices Push Merck Up 54% [Published Drug Discovery and Development - May 14 2013]
Alzheimer's Predicted Before Symptoms Develop [Published Drug Discovery and Development - May 14 2013]
Pfizer Having Second Thoughts on Remoxy [Published Drug Discovery and Development - May 10 2013]
ASMS Conference on Mass Spectrometry and Allied... [Published Drug Discovery and Development - May 10 2013]
Almac Out-Licenses ALM201 [Published Drug Discovery and Development - May 10 2013]
AIDS Research May Tackle Drug-Resistant Bacteria [Published Drug Discovery and Development - May 10 2013]
Alexza Licenses Adasuve to Teva [Published Drug Discovery and Development - May 09 2013]
A Target Rich Environment [Published Drug Discovery and Development - May 09 2013]
Producing Orally Bioavailable Biologics [Published Drug Discovery and Development - May 07 2013]
Actavis Posts 1Q Loss [Published Drug Discovery and Development - May 03 2013]
Costs Increases Hit Pharmacyclics [Published Drug Discovery and Development - May 02 2013]
Firm May Lower Merck Rating [Published Drug Discovery and Development - May 02 2013]
Companion Diagnostics Keep Drug Development on ... [Published Drug Discovery and Development - May 02 2013]
Likely Role Of "Parkinson's" Protein Found [Published Drug Discovery and Development - May 01 2013]
Competition Cuts Merck Profit [Published Drug Discovery and Development - May 01 2013]
Daiichi Sankyo Sponsoring Perosphere Trial [Published Drug Discovery and Development - May 01 2013]
Dynamic Protein Drives Membrane Remodeling [Published Drug Discovery and Development - May 01 2013]
Pfizer Profits Up, But Outlook Down [Published Drug Discovery and Development - Apr 30 2013]
Microscope Can Visualize Nanostructures [Published Drug Discovery and Development - Apr 30 2013]
Molecule Offers Hope for Muscular Dystrophy [Published Drug Discovery and Development - Apr 30 2013]
Electroporation Key to Skin Cancer Treatment [Published Drug Discovery and Development - Apr 30 2013]
EMA Panel Recommends Nuedexta [Published Drug Discovery and Development - Apr 29 2013]
Bayer Paying $1.1B For Conceptus [Published Drug Discovery and Development - Apr 29 2013]
Raindance Working with Clients [Published Drug Discovery and Development - Apr 26 2013]
Eisai Building New Production Plant [Published Drug Discovery and Development - Apr 25 2013]
Microplate Readers Come with Specialty Software [Published Drug Discovery and Development - Apr 24 2013]
Analysis Module Improves Bioreactor System [Published Drug Discovery and Development - Apr 24 2013]
Disappointing Q1 Results from Ironwood [Published Drug Discovery and Development - Apr 24 2013]